Alzheon
Founded Year
2013Stage
Series E | AliveTotal Raised
$241.97MLast Raised
$100M | 2 yrs agoAbout Alzheon
Alzheon focuses on the development of medicines for neurodegenerative disorders, specifically within the healthcare and biotechnology sectors. The company's main product is an oral small-molecule prodrug that aims to block the formation of neurotoxic soluble amyloid oligomers in the brain, which is a key factor in the progression of Alzheimer's disease. Alzheon primarily serves the healthcare industry, with a specific focus on patients suffering from Alzheimer's disease and other neurological disorders. It was founded in 2013 and is based in Framingham, Massachusetts.
Loading...
Loading...
Expert Collections containing Alzheon
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Alzheon is included in 1 Expert Collection, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,249 items
Alzheon Patents
Alzheon has filed 15 patents.
The 3 most popular patent topics include:
- rare diseases
- neurological disorders
- alzheimer's disease
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
7/30/2019 | 9/10/2024 | Alzheimer's disease, Rare diseases, Neurodegenerative disorders, Cognitive disorders, Psychiatric diagnosis | Grant |
Application Date | 7/30/2019 |
|---|---|
Grant Date | 9/10/2024 |
Title | |
Related Topics | Alzheimer's disease, Rare diseases, Neurodegenerative disorders, Cognitive disorders, Psychiatric diagnosis |
Status | Grant |
Latest Alzheon News
Sep 18, 2024
FRAMINGHAM, Mass.--(BUSINESS WIRE)-- #ALZ801--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and related neurodegenerative disorders, today announced a new scientific publication describing its APOLLOE4 Phase 3 study, the first Phase 3 trial focused on AD patients carrying two copies of apolipoprotein ε4 allele (APOE4/4 homozygotes), a population with pressing unmet medical n
Alzheon Frequently Asked Questions (FAQ)
When was Alzheon founded?
Alzheon was founded in 2013.
Where is Alzheon's headquarters?
Alzheon's headquarters is located at 111 Speen Street, Framingham.
What is Alzheon's latest funding round?
Alzheon's latest funding round is Series E.
How much did Alzheon raise?
Alzheon raised a total of $241.97M.
Who are the investors of Alzheon?
Investors of Alzheon include Alerce Medical Technology Partners, National Institute on Aging, Paycheck Protection Program, Ally Bridge Group and ARCH Venture Partners.
Loading...
Loading...